Skip to main content

Day: March 22, 2022

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D., as chief executive officer (CEO). Dr. Sandrock succeeds Michael Higgins, who served as interim CEO since June 2021, and continues to serve as Chairman of the Voyager Board of Directors. “I am excited to welcome Al Sandrock as CEO. Al is a global thought leader in neuroscience with an impressive track record bringing transformative new medicines to patients,” said Mr. Higgins. “His success pioneering the development...

Continue reading

Christina Lake Cannabis Corp. Announces Redemption of Class B Preferred Shares

VANCOUVER, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) — (CSE: CLC) Christina Lake Cannabis Corp. (the “Corporation or “Christina Lake”) announces that, further to the press release issued on March 11, 2022, whereby the Corporation announced certain amendments to the terms of its class B preferred shares (“Preferred Shares“), the board of directors of the Corporation has now provided notice to the holders of Preferred Shares (the “Preferred Holders“), for a compulsory redemption of their Preferred Shares, which is intended to be completed on or about March 25, 2022, in accordance with the revised terms of the Preferred Shares (the “Redemption“). In connection with the Redemption, the Preferred Holders, which in aggregate hold 2,000,000 Preferred Shares, will be issued in aggregate: (i)...

Continue reading

Enthusiast Gaming Ranked as Largest Gaming Property in the United Kingdom and Canada

Reached 12.6M Unique Visitors in the U.K. and 6.8M Unique Visitors in Canada in January 2022, across web and video combined Combined Unique Visitor reach ahead of Roblox, Twitch, Activision Blizzard and IGN Entertainment in both markets LOS ANGELES, March 22, 2022 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ: EGLX; TSX: EGLX), an integrated gaming entertainment company, today announced that its digital media property ranked as the largest property in the Games category in the United Kingdom and Canada, based on recent digital media ratings from Comscore, a leading third-party media measurement firm. In the U.K., Enthusiast Gaming reached a combined 12.6 million Unique Visitors across web and video in January 2022, claiming the top spot among all gaming digital media properties: Top...

Continue reading

Mosaic Minerals Adds Claims on Gaboury

Gaboury Project Magnetic Anomalies Gaboury Project Magnetic AnomaliesMONTREAL, March 22, 2022 (GLOBE NEWSWIRE) — Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or the “the Corporation”) adds 19 claims covering an area of 791 hectares on the western edge of its Gaboury property, located in Quebec’s Témiscamingue region. This project is now composed of 114 claims for a total area of 6,064 hectares. Thirteen of these new claims were acquired by map staking while the other six were acquired from an independent prospector, in return for a cash payment of $10,000. No royalty is subject to these new claims. The Gaboury property contains several nickel, copper, and gold showings. However, the management of the Company is concentrating its activities on the search for nickel along a magnetic anomaly crossing it for nearly 9 km, in...

Continue reading

Uxin to Report Third Quarter Fiscal Year 2022 Financial Results on March 29, 2022

BEIJING, March 22, 2022 (GLOBE NEWSWIRE) — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), a leading nationwide online used car dealer in China, today announced that it will report its unaudited financial results for the third quarter of fiscal year 2022 ended December 31, 2021 before the open of U.S. markets on March 29, 2022. Uxin’s management team will host a conference call on Tuesday, March 29, 2022, at 8:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong time on the same day) to discuss the financial results. In advance of the conference call, all participants must use the following link to complete the online registration process. Upon registering, each participant will receive access details for this conference including Direct Event passcode, a unique registrant ID, dial-in numbers, and an e-mail with detailed...

Continue reading

FreightCar America, Inc. Reports Fourth Quarter and Full Year 2021 Results

Fiscal Year 2021 revenue up 87% and year-end order book increased 67% versus 2020 Company expects continued strong progress in 2022 with sequential improvement in gross margin and is raising full year delivery guidance CHICAGO, March 22, 2022 (GLOBE NEWSWIRE) — FreightCar America, Inc. (“FCA” or the “Company”) (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today reported results for the fourth quarter and full year ended December 31, 2021. Business Highlights        Fourth quarter 2021 revenue of $75.0 million, up 23.8% year-over-year, on deliveries of 604 railcars Gross margin of $6.6 million, positive for the fifth consecutive quarter Manufacturing operating income of $4.9 million, positive for the third consecutive quarter Fourth quarter 2021 net income of $1.2 million, or $0.06 per share Fourth quarter...

Continue reading

GDS Holdings Limited Reports Fourth Quarter and Full Year 2021 Results

SHANGHAI, China, March 22, 2022 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial HighlightsNet revenue increased by 34.1% year-over-year (“Y-o-Y”) to RMB2,187.4 million (US$343.2 million) in the fourth quarter of 2021 (4Q2020: RMB1,631.6 million). Service revenue increased by 34.3% Y-o-Y to RMB2,185.9 million (US$343.0 million) in the fourth quarter of 2021 (4Q2020: RMB1,627.5 million). Net loss was RMB312.9 million (US$49.1 million) in the fourth quarter of 2021, compared with a net loss of RMB271.5 million in the fourth quarter of 2020. Adjusted EBITDA (non-GAAP)...

Continue reading

Science 37 Reports Fourth Quarter and Full Year 2021 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 22, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter and full year ended December 31, 2021. “Our impressive financial performance in the fourth quarter and for the full year 2021 reflects our team’s continued strong execution and commitment to expanding patient access and reach of our agile clinical trial offerings,” said David Coman, Chief Executive Officer of Science 37. “As we look ahead to 2022, we expect a sustained market shift toward more decentralization and strong demand for our differentiated Operating System. We are on a clear pathway to growth and long-term profitability as we redefine the future of clinical research; and we are confident that we are well...

Continue reading

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022 Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved Presented key FREEDOM-HF secondary endpoint data at the Cardiovascular Research Foundation Technology and Heart Failure Therapeutics Conference 2022 Ended Q4 with cash, cash equivalents, restricted cash and investments of $75.5 million BURLINGTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business...

Continue reading

TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the fourth quarter ended December 31, 2021 and provided a corporate update. “Consistent execution throughout the last year has positioned TCR2 for a series of important readouts as we accelerate our clinical progress in 2022,” said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. “We were able to successfully conclude the dose escalation portion of our ongoing gavo-cel Phase 1/2 clinical trial with the identification of a RP2D and submit a protocol amendment with the FDA for the upcoming Phase 2 clinical trial. We also submitted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.